Noninvasive encapsulated follicular variant of papillary thyroid carcinoma, a diagnosis implying malignancy as a variant of papillary thyroid carcinoma (PTC), has recently been reclassified to noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) on surgical pathology. Due to the effects of such a recategorization on rate of malignancy and clinical management algorithms, it is imperative that we explore whether presurgical fineneedle aspiration can differentiate NIFTP from PTC and follicular adenoma (FA). METHODS: Cytology slides from subjects with final surgical pathology resection diagnoses of NIFTP/encapsulated follicular variant of papillary thyroid carcinoma, classic PTC, and FA made between January 2013 and August 2016 were assessed. The Bethesda System diagnoses were tabulated and cytomorphologic features were analyzed for an association with surgical pathology diagnoses. RESULTS: A total of 56 NIFTP, 67 classic PTC, and 30 FA cases were included. The presurgical NIFTP diagnosis according to The Bethesda System was most often atypia of undetermined significance (37.5%) followed by suspicious for follicular neoplasm/follicular neoplasm (26.8%), suspicious for malignancy (17.9%), benign (10.7%), and positive for malignancy (7.1%).
INTRODUCTION
Papillary thyroid carcinoma (PTC), the most common malignant neoplasm of the thyroid gland, generally has an indolent course and a favorable prognosis. 1 One of the most prevalent variants of PTC is the follicular variant of PTC (FVPTC), which has the lowest mortality rate among all types of PTC. [2] [3] [4] [5] [6] The noninvasive encapsulated follicular variant of papillary carcinoma (EFVPTC) in particular is reported to have a low risk of adverse outcomes and disease recurrence, similar to follicular adenoma (FA), and therefore recently was reclassified as "noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) ." This reclassification signified that it is no longer considered a malignant entity, 2 thus impacting the presurgical rate of malignancy (ROM) 7, 8 as well as management triage. 2 Histologically, NIFTP appears to fall within a spectrum between FAs and PTCs. As established by the Endocrine Pathology Society working group, the surgical pathology diagnostic criteria for NIFTP include a 3-tiered semiquantitative grading system for "papillary-like" nuclear features with a score of 2/3 or 3/3 (nuclear enlargement, elongation, and crowding/overlapping; membrane irregularities, grooves, and pseudoinclusions; and chromatin clearing/margination and/or glassy nuclei) and features of FAs including encapsulation/clear demarcation; follicular growth pattern with <1% papillae; no psammoma bodies; <30% solid/trabecular/insular growth pattern; and the absence of high mitotic activity, invasion, or necrosis. 2 Management often is determined at the time of presurgical fine-needle aspiration (FNA) biopsy. However, to the best of our knowledge, there are no established criteria for the presurgical diagnosis of NIFTP and its distinction from FA and/or classic PTC. Due to its indolent nature, avoidance of overtreatment is warranted. Therefore, it is imperative that we explore whether there are cytomorphologic differences at the FNA stage of patient care among NIFTP, classic PTC, and FA. The current study examines presurgical The Bethesda System (TBS) diagnoses and the cytomorphologic features of NIFTP, classic PTC, and FA cases to determine whether cytology can distinguish these entities. To our knowledge, the current study represents the largest cytomorphology study performed to date comparing presurgical FNA cytology features and diagnoses among NIFTP, PTC, and FA cases.
MATERIALS AND METHODS
The current study protocol was approved by the New York University Cancer Institute Protocol Review and Monitoring Committee and by the New York University Institutional Review Board. A search was conducted in our laboratory information system for thyroid surgical pathology cases of EFVPTC/NIFTP (henceforth, this category will be referred to as NIFTP), classic PTC, and FA from January 2013 to August 2016. Cases lacking a preceding in-house FNA of the same nodule (as determined by correlation between radiologic findings, biopsy site, and location in the surgical specimen) were excluded. For any subject with multiple FNAs of the same nodule, only the most recent FNA specimen was included.
A total of 21 cases of EFVPTC were excluded due to the presence of capsular invasion. All EFVPTC and NIFTP surgical pathology cases considered for the current study were reviewed by 2 pathologists (T.C.B and C.Z.L) to determine the presence or absence of invasion. EFVPTC cases demonstrating any vascular or capsular invasion (including minimal invasion) were excluded from the study. Cases in which the entire capsule was not submitted or the surgical pathology slides were unable to be retrieved (for confirmation of invasion or lack thereof) also were excluded. In the majority of the cases, the entire tumor and capsule were submitted. In 4 cases, the entire capsule was submitted with representative sections from the remainder of the tumor. NIFTP histology slides were given nuclear scores according to the 3-tiered semiquantitative grading system for "papillary-like" nuclear features, 2 and were semiquantitatively assessed for the extent of atypia. Histologic nuclear scores and extent of atypia were compared with cytology diagnoses. PTC cases were excluded if they were not of the classic variant, and if they were from nodules measuring <1 cm. Because PTC was a comparison group (with the goal of reaching a number that was comparable to the NIFTP study group), once a sufficient number of cases were determined to meet study inclusion criteria in reverse chronological order, the remainder of the PTC cases were excluded. FNA cases preceding surgical pathology diagnoses of NIFTP, PTC, and FA were retrieved for 56 cases, 67 cases, and 30 cases, respectively, and the original TBS cytology diagnoses were tabulated. Each case was reviewed by 2 pathologists (T.C.B. and W.S.), who were both blinded to the original cytology and subsequent surgical pathology diagnoses. They reviewed the cases at a multiheaded microscope for the presence of nuclear pseudoinclusions, grooves (easily visualized, difficult to observe but present, or absent), crowding, enlargement, nuclear contour irregularities, and clearing, as well as papillae, calcifications, microfollicles, colloid (abundant, some, or rare), and giant cells. The assessment of each feature as present or absent followed the criteria outlined in TBS with a balance between quality and quantity taken into consideration.
FNA Collection
Ultrasound-guided thyroid FNA was performed by radiologists, endocrinologists, or cytopathologists with 23-gauge to 27-gauge needles with approximately 2 to 4 passes. Diff-Quik-stained and ultrafast Papanicolaou-stained, airdried smears were prepared. Each case consisted of 4 to 10 cytology slides.
Statistical Analysis
Statistical analyses were conducted using SPSS statistical software (version 23; IBM Corporation, Armonk, NY). The Welch Student t test was performed to compare means among groups. Associations between categorical variables were assessed by chi-square tests, including the Fisher exact tests for 2 3 2 tables. All reported P values were 2-sided, with statistical significance defined as P<.05.
RESULTS
A total of 56 NIFTP cases, 67 classic PTC cases, and 30 FA cases were included in the current study. For PTC, NIFTP, and FA cases, the mean ages of the patients were 46.5 years, 48.1 years, and 45.6 years, respectively (P 5 0.8); sex was predominantly female for all groups (65.7%, 66.1%, and 73.3%, respectively; P 5 0.7); and the mean nodule sizes were 1.8 cm, 2.4 cm, and 3.1 cm, respectively (P<.001). Each of the 56 NIFTP cases received a score of 1/1 for histologic nuclear grade in the "size and shape" category. A total of 43 cases received a "nuclear membrane irregularity" score of 1/1 and 48 cases received a score of 1/ 1 for "chromatin characteristics" (Fig. 1) . There was no statistically significant association found between histologic nuclear grade and the original cytology diagnoses, or between the histologic extent of atypia and the original cytology diagnoses. Only 1 case of NIFTP was found to have lymph node metastasis arising from a separate PTC nodule. Table 1 shows the distribution of TBS diagnoses for PTC, NIFTP, and FA. No cases had a nondiagnostic (TBS category I) presurgical diagnosis. PTC cases were found to have TBS diagnoses of positive for malignancy (PosM), suspicious for malignancy (SusM), and atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) in 86.6%, 7.5%, and 6.0% of cases, respectively. NIFTP cases were found to have TBS diagnoses of AUS/FLUS, suspicious for follicular neoplasm or follicular neoplasm (FN), SusM, benign, and PosM in 37.5%, 26.8%, 17.9%, 10.7%, and 7.1% of cases, respectively. FA cases were found to have TBS diagnoses of AUS/FLUS, FN, and benign in 36.7%, 30%, and 33.3% of cases, respectively.
All cytomorphologic features examined were found to be significantly associated with surgical pathology diagnoses when comparing NIFTP with PTC cases, whereas only select features demonstrated significant associations when comparing NIFTP with FA cases (Tables 2 and 3) . Compared with NIFTP cases, PTC cases more often demonstrated nuclear pseudoinclusions (86.6% in PTC vs 8.9% in NIFTP), papillae (70.1% in PTC vs 5.4% in NIFTP), nuclear crowding (98.5% in PTC vs 82.1% in NIFTP), nuclear enlargement (98.5% in PTC vs 83.9% in NIFTP), nuclear contour irregularities (46.3% in PTC vs 10.7% in NIFTP), nuclear clearing (97% in PTC vs 69.6% in NIFTP), calcifications (22.4% in PTC vs 3.6% in NIFTP), giant cells (41.8% in PTC vs 7.1% in NIFTP), and easily visualized nuclear grooves (88% in PTC vs 35.7% in NIFTP) (Fig. 2) . NIFTP cases demonstrated several nuclear features more often than FA: nuclear crowding (82.1% in NIFTP vs 36.7% in FA), nuclear enlargement (83.9% in NIFTP vs 26.7% in FA), nuclear clearing (69.6% in NIFTP vs 16.7% in FA), and easily visualized nuclear grooves (35.7% in NIFTP vs 3.3% in FA) (Fig. 3) . No cases of FA demonstrated nuclear pseudoinclusions, papillae, nuclear contour irregularities, or calcifications (Fig. 4) . NIFTP and FA cases were found to more often demonstrate microfollicles (73.2% and 90%, respectively) whereas microfollicles were observed in merely 3% of PTC cases. The PTC, NIFTP, and FA groups more often demonstrated rare to no colloid (56.7%, 53.6%, and 66.7%, respectively) compared with abundant colloid (10.5%, 28.6%, and 23.3%, respectively).
DISCUSSION
The findings of the current study demonstrate that there are statistically significant associations between cytomorphologic features on FNA cytology and subsequent surgical pathology diagnoses, which can be used as clues to recognize the presurgical possibilities of classic PTC, NIFTP, and FA.
NIFTP demonstrated cytomorphologic features of both PTC and FA, which should be one of the key a priori clues to a diagnosis of NIFTP. For example, an FNA specimen that demonstrates PTC nuclear features and Distinguishing NIFTP, PTC, and FA on FNA/Brandler et al
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June 2017 microfollicles should trigger concern for NIFTP. No one or two features alone should be used to predict the diagnosis, but a combination of the entire panel of features should be considered. Similar to FAs, NIFTP diagnoses ultimately must be made based on the surgical specimen, with a careful examination of the tumor (to exclude the presence of >1% papillae, >30% solid growth, and features of poorly differentiated carcinoma) and a thorough examination of the tumor capsule (to ensure a lack of infiltrative growth, capsular invasion, and vascular invasion). 2, 9 However, the necessity for histologic assessment and the ability to achieve concern for a diagnosis of NIFTP based on cytology alone are not mutually exclusive. The results of the current study have shown that the cytopathologist can raise concerns for a diagnosis of NIFTP at the cytologic level based on the cytomorphologic features. This situation is analogous to TBS category IV (FN), in which the cytopathologist raises the possibility of follicular carcinoma (FC) but the distinction between FA and FC must be made at the histologic level.
Presurgical suspicion of NIFTP can and should be taken into consideration in the management algorithm because the literature has shown NIFTP to be a low-risk neoplasm necessitating less extensive treatment (lobectomy rather than total thyroidectomy, without the addition of radioactive iodine ablation; again analogous to TBS category IV).
2-6,9-13 In addition, the impact of removing NIFTP from the malignant PTC category already has been demonstrated to decrease the ROM in all 6 TBS categories, with the most significant decrease noted in the indeterminate categories. 7, 8 Similarly, in our institution, according to preliminary data gathered for 2015, the ROM changed from 5% to 0% in the benign category, 36% to 20% in the AUS/FLUS category, 42% to 6% in the FN category, 95% to 63% in the SusM category, and 100% to 99% in the PosM category, 14 thereby further supporting the goal of avoiding overtreatment in such cases.
The results of the current study demonstrate that at the presurgical stage of patient care, NIFTP, PTC, and FA have distinguishing features, both in cytomorphology and in their TBS diagnoses. These findings are supported by Strickland et al (Table 4) , [15] [16] [17] [18] [19] who found a statistically significant association between several cytomorphologic features (papillae, pseudoinclusions, and microfollicular pattern) and histologic diagnoses (including PTC and NIFTP). However, the study by Strickland et al only examined FNA cases with a SusM or a PosM cytology diagnosis, which therefore led to a very limited sample size of NIFTP cases for analysis (8 cases) and also may have led to a bias in their results. 15 The results in the study The findings of the current study are supported further by Howitt et al, who found a significant difference in cytomorphologic features (tumor sheets, microfollicles, papillae, and pseudoinclusions) between the NIFTP and PTC groups. 16 In their study, PTC cases demonstrated tumor sheets in 96% of cases, papillae in 50% of cases, pseudoinclusions in 79% of cases, and microfollicles in only 4% of cases compared with NIFTP cases, of which 0% had papillae or pseudoinclusions, 36% had tumor sheets, and 55% had microfollicles (P 5 .0009). 16 Similar to Ibrahim et al, 17 who found that FNAs preceding NIFTP were most frequently diagnosed as AUS/ FLUS, we found that 46 NIFTP cases in the current study (82.1%) were in indeterminate categories, with 21 cases (37.5%) diagnosed as AUS/FLUS on preceding cytology. 17 Maletta et al found a significant correlation between nuclear features present in NIFTP cases and their preceding FNA cytology. 18 This finding indicates that concern for a NIFTP diagnosis can be raised at the time of FNA. It is interesting to note that the NIFTP cases in the study by Maletta et al were preceded by FNA TBS diagnoses of AUS (15%), FN (56%), SusM (27%), and PosM (2%). 
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Similar to the current study, Bizzarro et al found significant differences between the NIFTP and PTC groups with regard to cytomorphologic features such as nuclear size, the presence of pseudoinclusions, grooves, nuclear membrane irregularities, and several background and architectural features (presence of papillae, isolated cells, molding, and papillary vs follicular architecture) as well as significant differences between NIFTP and FA with regard to nuclear size, shape, chromatin density, presence of grooves, nuclear membrane irregularities, molding, and nuclear-tocytoplasmic ratio. 19 Before the reclassification of EFVPTC to NIFTP, all thyroid tumors with papillary carcinoma-like nuclear features were considered malignancies (ie, FVPTC); thus, such cases used to be confidently and correctly diagnosed on cytology as PosM. However, after the reclassification, not all cases of "FVPTC" will be classified as malignant. It is essential for cytopathologists to keep this in mind when formulating diagnoses on cytology cases that demonstrate features of both PTC and FA.
Review of the 4 histologically confirmed NIFTP cases in the current study diagnosed as PosM on FNA (7.1%) demonstrated that none of these cases demonstrated papillae and all demonstrated microfollicular architecture. All cases were found to have nuclear grooves and all but one case demonstrated easily visible grooves. All 4 cases demonstrated nuclear enlargement and nuclear clearing; only 1 case demonstrated nuclear pseudoinclusions and nuclear contour irregularities; and no cases were found to have calcifications, colloid, or giant cells. The pathologists in the current study blindly reviewed these 4 cases, and 1 case was still termed PosM whereas 3 cases were downgraded to indeterminate categories and termed FN (1 case) or SusM (2 cases). A possible explanation for this is that because pathologists are aware of the recent recategorization of NIFTP from a malignant to a benign entity, the possibility of NIFTP is kept in mind when reviewing cases that demonstrate a follicular pattern and nuclear features of PTC. This is the likely explanation for why these cases, upon blind review, were no longer considered PosM. This then would lower the percentage to 1.8% of NIFTP cases being called PosM (from 7.1%). It is interesting to note that each TBS category is associated with a certain risk of malignancy, and even the PosM category is not 100% predictive of malignancy (rather 97%-99%). The inherent limitations of cytology are addressed by the TBS by the assignment of a range for a ROM for each TBS category.
In addition to NIFTPs demonstrating a lower risk of clinical adverse effects as well as histologic and cytomorphologic characteristics dissimilar from those of PTC, NIFTP also has been shown to be more similar to FA on the molecular level, demonstrating more frequent mutations in RAS and paired box gene 8 (PAX8)/peroxisome proliferator-activated receptor gamma (PPARc) fusions than BRAF V600E (a mutation more typically associated with classic PTC). 2, 5, 13, 16, 20 On the molecular level, NIFTP (harboring RAS and PAX8/PPARc) is not only different from classic PTC (harboring BRAF), but also is different from invasive FVPTC (also harboring BRAF) according to some studies. 13, 16, 19 In addition, microRNAs have the potential to be even more specific in distinguishing NIFTP from invasive FVPTC compared with the aforementioned mutations alone. 21 Maletta et al found that NIFTP and invasive EFVPTC could not be distinguished at the cytologic level, and reported no significant differences between the 2 groups with regard to cytomorphologic features (nuclear size, nuclear membrane irregularities, and chromatin clearing). 18 However, Maletta et al did find a significant difference in cytomorphologic features between NIFTP and the benign follicular lesion group. 18 Bizzarro et al found that NIFTP and invasive EFVPTC were significantly different with regard to nuclear size and the presence of nuclear 17 The distinction between NIFTP and invasive EFVPTC ultimately requires a thorough examination of the tumor capsule on histology to determine the presence or absence of invasion. Due to the difficulty in distinguishing between invasive and noninvasive FVPTC on cytology (a difficulty similar to that experienced by cytopathologists in the distinction between FA vs FC on cytology), we chose to compare NIFTP with classic PTC at the malignant end of the spectrum, and with FA at the benign end of the spectrum. It is imperative to keep in mind the balance that must be maintained between false-positive diagnoses of NIFTP cases and false-negative diagnoses of similarappearing FNA specimens of invasive FVPTC, which cannot be reliably distinguished on cytology. This is a similar conundrum faced when examining FAs versus follicular carcinomas, a diagnostic distinction that is never made on cytology. Although the follicular pattern and nuclear features of PTC may be suggestive of NIFTP, they also may be suggestive of invasive FVPTC; therefore, this is still a surgical entity, and the distinction must be made based on the surgical specimen.
Some institutions may require a disclaimer note on cytology reports accompanying a diagnosis for the indeterminate categories. However, at the current study institution, which is a large academic medical center, the clinicians are in constant communication with the pathologists and with evolving concepts in pathology; therefore, we do not require such a disclaimer. The issue of whether to include a disclaimer regarding NIFTP is entirely dependent on the institution.
Despite the statistically significant associations noted among cytomorphologic features and surgical pathology diagnoses, by no means do we recommend raising a suspicion for NIFTP based on only one, or even many, cytomorphologic features. Although the data in the current study and preceding literature highlight the need for cytopathologists to readjust their diagnostic algorithm to emphasize the subtle but discernible cytomorphologic features of NIFTP, these features need to be considered in the overall clinical context. The TBS cytologic diagnosis, as well as the clinical and radiologic findings, all must be considered before the cytopathologist raises the possibility of NIFTP to recommend a less aggressive treatment course.
A study examining the molecular profiles of NIFTP cases with preceding cytology would complement the current study findings and further elucidate the ideal management of potential NIFTP cases at the FNA stage of a thyroid nodule workup. A recent study by Jiang et al examined the molecular signatures of 8 NIFTP cases and found 4 cases (diagnosed as AUS/FLUS on cytology) to be "suspicious" using the Afirma gene expression classifier (Veracyte Inc, South San Francisco, Calif), and 4 cases (3 diagnosed as AUS/FLUS and 1 as FN on cytology) to have RAS mutations upon ThyroSeq v2 testing. 22 These parameters should be explored at the study institution to validate these findings and add to the limited existing literature regarding the molecular characteristics of NIFTP cases.
In addition, future studies should include clinical and radiologic assessments to explore whether these features, also at the earlier stage of management, contribute to the distinction between NIFTP, PTC, and FA. The current study, which explored NIFTP cytomorphologic features, also should be followed up by interobserver variability studies and ultimately multi-institutional validation studies to determine whether a new TBS category should be considered.
The possibility of NIFTP can be suspected at the time of FNA, as the results of the current study have shown significant associations among cytomorphologic features and these 3 surgical diagnoses. However, the shortcomings of FNA cytology must be reemphasized. A diagnosis of NIFTP may be suggested but cannot be confirmed until a full surgical pathology evaluation has been performed. The clinical, ethical, monetary, and potentially medicolegal ramifications of being able to distinguish between features of NIFTP and PTC at the time of FNA during a thyroid nodule workup are great in that a more conservative management approach can be initiated, with the goal of avoiding overtreatment. The potential difference in treatment triage underscores the importance of strong interdepartmental communication and a multidisciplinary approach to patient care.
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